CD52 and myeloid sarcoma: While there is limited literature on the effect of therapy on IgG4 in MS, a clinical study involving 29 Greek RR-MS patients demonstrated an increase in IgG4 levels after 24 months of treatment with alemtuzumab, a monoclonal antibody targeting CD52 [36].